E
Calliditas Therapeutics AB (publ) CALT
NASDAQ
Recommendation
Prev Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)

06/30/2024 03/31/2024 12/31/2023 09/30/2023 06/30/2023
Net Income 49.16% -31.92% -402.62% -1,701.91% 55.38%
Total Depreciation and Amortization -- -- 29.45% -- --
Total Amortization of Deferred Charges -- -- -- -- --
Total Other Non-Cash Items 433.00% 93.80% 22.20% 245.71% -72.25%
Change in Net Operating Assets 35.64% 122.01% -115.98% 168.98% -119.09%
Cash from Operations 95.75% 14.12% -90.00% 51.11% 32.39%
Capital Expenditure -- -- -412.88% -- --
Sale of Property, Plant, and Equipment -- -- -- -- --
Cash Acquisitions -- -- -- -- --
Divestitures -- -- -- -- --
Other Investing Activities 90.57% -33.09% 904.40% -714.23% -614.18%
Cash from Investing 90.57% -33.09% -61.72% -714.23% -614.18%
Total Debt Issued -- -- 277.18% -- --
Total Debt Repaid -34.66% -84.14% -25,336.60% -12.42% -19.31%
Issuance of Common Stock -- -- -- -- --
Repurchase of Common Stock -- -- -- -- --
Issuance of Preferred Stock -- -- -- -- --
Repurchase of Preferred Stock -- -- -- -- --
Total Dividends Paid -- -- -- -- --
Other Financing Activities -- -- -2,009.83% -- --
Cash from Financing -32.08% -85.08% -25.68% -9.64% -101.19%
Foreign Exchange rate Adjustments -109.24% 1,804.85% -2,552.26% -135.93% 68.74%
Miscellaneous Cash Flow Adjustments -- -- -200.00% -- --
Net Change in Cash 91.29% 30.26% -63.30% 30.11% -743.69%
Weiss Ratings